BACKGROUND: The objective of the present meta-analysis was to estimate the magnitude of survival and recurrence free benefits from different lymphadenectomy in patients with resectable gastric cancer. METHODS: A comprehensive search was performed for original studies published from their inception to 2012. Two reviewers independently assessed search results, methodological quality, and data extraction of included studies. Results regarding the overall survival (OS) and recurrence free survival (RFS) in the meta-analysis were expressed as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: Twelve randomized control trials (RCTs) were eligible for final meta-analysis. There was not significant difference in OS between D1 and D2 lymphadenectomy (HR = 0.92, 95% CI: 0.77-1.10, P = 0.36), but subgroup analysis of patients without splenectomy and/or pancreatectomy has a trend for OS much more benefiting D2 compared to D1 patients. A significant RFS improvement was found in favor of D2 lymphadenectomy, sensitivity analysis also gives similar fixed effect estimates (HR = 0.68, 95% CI: 0.58-0.81, P = 0.84). There were no significant differences in OS and RFS between D2 group and D3 group (1 trial). CONCLUSIONS: The present meta-analysis indicates that D2 lymphadenectomy with spleen and pancreas preservation offers the most survival benefit for patients with gastric cancer when done safety.
BACKGROUND: The objective of the present meta-analysis was to estimate the magnitude of survival and recurrence free benefits from different lymphadenectomy in patients with resectable gastric cancer. METHODS: A comprehensive search was performed for original studies published from their inception to 2012. Two reviewers independently assessed search results, methodological quality, and data extraction of included studies. Results regarding the overall survival (OS) and recurrence free survival (RFS) in the meta-analysis were expressed as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: Twelve randomized control trials (RCTs) were eligible for final meta-analysis. There was not significant difference in OS between D1 and D2 lymphadenectomy (HR = 0.92, 95% CI: 0.77-1.10, P = 0.36), but subgroup analysis of patients without splenectomy and/or pancreatectomy has a trend for OS much more benefiting D2 compared to D1 patients. A significant RFS improvement was found in favor of D2 lymphadenectomy, sensitivity analysis also gives similar fixed effect estimates (HR = 0.68, 95% CI: 0.58-0.81, P = 0.84). There were no significant differences in OS and RFS between D2 group and D3 group (1 trial). CONCLUSIONS: The present meta-analysis indicates that D2 lymphadenectomy with spleen and pancreas preservation offers the most survival benefit for patients with gastric cancer when done safety.
Authors: M Martín-Richard; A Carmona-Bayonas; Ana B Custodio; J Gallego; P Jiménez-Fonseca; J J Reina; P Richart; F Rivera; M Alsina; J Sastre Journal: Clin Transl Oncol Date: 2020-01-27 Impact factor: 3.405
Authors: Roman Yarema; Giovanni de Manzoni; Taras Fetsych; Myron Ohorchak; Mykhailo Pliatsko; Maria Bencivenga Journal: World J Gastrointest Oncol Date: 2016-06-15
Authors: Alexandre Gosselin-Tardif; Jessica Lie; Ioana Nicolau; Juan Carlos Molina; Jonathan Cools-Lartigue; Liane Feldman; Jonathan Spicer; Carmen Mueller; Lorenzo Ferri Journal: J Gastrointest Surg Date: 2017-11-09 Impact factor: 3.452
Authors: Giuseppe Verlato; Simone Giacopuzzi; Maria Bencivenga; Paolo Morgagni; Giovanni De Manzoni Journal: World J Gastroenterol Date: 2014-09-28 Impact factor: 5.742